Equities research analysts expect that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report $0.18 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Tabula Rasa HealthCare’s earnings, with estimates ranging from $0.10 to $0.25. Tabula Rasa HealthCare reported earnings per share of $0.26 during the same quarter last year, which suggests a negative year over year growth rate of 30.8%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full year earnings of $0.81 per share for the current year, with EPS estimates ranging from $0.61 to $0.94. For the next year, analysts anticipate that the firm will report earnings of $1.13 per share, with EPS estimates ranging from $0.75 to $1.53. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.29. The firm had revenue of $76.26 million for the quarter, compared to analysts’ expectations of $70.40 million. Tabula Rasa HealthCare had a positive return on equity of 3.63% and a negative net margin of 7.09%. The firm’s revenue for the quarter was up 56.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS.

A number of equities research analysts have weighed in on the company. BidaskClub lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Friday, October 11th. Stifel Nicolaus raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and lifted their price objective for the company from $50.00 to $75.00 in a report on Friday, August 30th. Piper Jaffray Companies set a $78.00 price objective on Tabula Rasa HealthCare and gave the company a “buy” rating in a report on Friday. ValuEngine raised Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $78.26.

In other news, Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $62.64, for a total transaction of $62,640.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $56.23, for a total value of $449,840.00. The disclosure for this sale can be found here. Insiders sold a total of 78,000 shares of company stock worth $4,492,530 in the last ninety days. 11.80% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the company. CWM LLC purchased a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth approximately $4,569,000. Janus Henderson Group PLC purchased a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth approximately $17,074,000. Peregrine Capital Management LLC boosted its stake in shares of Tabula Rasa HealthCare by 20.7% during the 2nd quarter. Peregrine Capital Management LLC now owns 335,984 shares of the company’s stock worth $16,776,000 after acquiring an additional 57,639 shares in the last quarter. Dana Investment Advisors Inc. boosted its stake in shares of Tabula Rasa HealthCare by 23.7% during the 2nd quarter. Dana Investment Advisors Inc. now owns 42,751 shares of the company’s stock worth $2,135,000 after acquiring an additional 8,196 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth approximately $6,241,000. 98.87% of the stock is currently owned by institutional investors and hedge funds.

TRHC stock traded down $0.09 during trading on Thursday, hitting $49.50. The company had a trading volume of 192,670 shares, compared to its average volume of 357,915. The firm has a market cap of $1.08 billion, a PE ratio of 145.59 and a beta of 1.66. Tabula Rasa HealthCare has a 1-year low of $40.86 and a 1-year high of $81.83. The firm has a 50-day moving average price of $54.23 and a 200-day moving average price of $53.18. The company has a quick ratio of 1.90, a current ratio of 1.97 and a debt-to-equity ratio of 1.31.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: What causes a recession?

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.